The Japanese company, Fujifilm said that they would be investing an approximate amount of $928 million towards the scaling up of its large-scale biologics production facility in Denmark.
The investment will be made directly in its Fujifilm Diosynth Biotechnologies site in Denmark. The company aims to scale up the drug substance production capacity of the biologics production facility by two. The company will be expanding its production lines for bulk drug substances by introducing an additional six mammalian cell bioreactors.
Additionally, the biologics production facility will have a total of 12 x 20,000-liter bioreactors by the third quarter of 2023. As part of its development plans, there will be the addition of the Danish site’s first fill/finish production line, scheduled for the first half of 2023.
The new production line will have a fully-automated system that can produce up to nearly 35 million units per annum to meet the requirements of large-scale production. Furthermore, a new packaging line equipped with facilities to assemble various types of auto-injectors will be adding to the Danish biologics production facility.
The biologics production facility in Denmark was acquired by FUJIFILM from Biogen for $890m back in August 2019.